Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
Not available.
Saved in:
| Main Authors: | Roberta S. Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G. Haddad, Alexis Geppner, Ghayas C. Issa, Koji Sasaki, Jayastu Senapati, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-06-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab
by: Nicholas J. Short, et al.
Published: (2025-05-01) -
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm
by: Suravi Raychaudhuri, et al.
Published: (2025-08-01) -
Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes
by: Marlise R. Luskin, et al.
Published: (2025-06-01) -
Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
by: Alaa Eldein Yahia, et al.
Published: (2025-01-01) -
Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)